DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/45frg4/friedreichs) has announced the addition of the "Friedreich's Ataxia Pipeline Highlights - 2014 Update" report to their offering.
The latest report Friedreich's Ataxia Pipeline Highlights - 2014 Update, provides most up-to-date information on key pipeline molecules in the global Friedreich's Ataxia market. It covers emerging therapies for Friedreich's Ataxia in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Friedreich's Ataxia pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Friedreich's Ataxia pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Friedreich's Ataxia pipeline molecules by the Originator Company.
Short-term Launch Highlights:
Find out which Friedreich's Ataxia pipeline products will be launched in the US and Ex-US till 2017.
Key Topics Covered:
1. Friedreich's Ataxia Pipeline by Stages
2. Friedreich's Ataxia Pipeline by Drug Class
3. Friedreich's Ataxia Pipeline by Company
4. Friedreich's Ataxia Phase 3 Clinical Trial Insights
5. Friedreich's Ataxia Phase 2 Clinical Trial Insights
6. Friedreich's Ataxia Phase 1 Clinical Trial Insights
7. Friedreich's Ataxia Preclinical Research Insights
8. Friedreich's Ataxia Discovery Stage Insights
10. Research Methodology
For more information visit http://www.researchandmarkets.com/research/45frg4/friedreichs